Boston Scientific upgraded at Oppenheimer As previously reported, Oppenheimer upgraded Boston Scientific to Overweight from Equal Weight. The firm upgraded shares to reflect pipeline acceleration and margin improvement in cardiology. Price target is $15.
News For BSX From The Last 14 Days
Check below for free stories on BSX the last two weeks.